Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2019-10-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
第八届监事会第十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the resolution of the 12th meeting of the 8th Supervisory Board. It details the resignation of a supervisor and the election of a new supervisor candidate, including voting results. The content focuses on board/management changes and meeting resolutions, with no financial data or report attached. The document length is short (986 characters) and it is clearly an announcement of board/management changes rather than a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG).
2019-10-09 Chinese
第八届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the convening of a second extraordinary shareholders' meeting in 2019. It includes details about the board meeting, attendance, voting results, and a director's abstention. There is no financial data, audit information, or detailed report content. It is an announcement of board/management decisions rather than a full report or regulatory filing. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not a report publication or regulatory filing.
2019-10-09 Chinese
关于对深圳证券交易所关注函回复的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. responding to a regulatory inquiry from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC). It details the company's reply to concerns about the actual controller of the company, related party transactions, and compliance with disclosure and approval procedures. The document includes extensive tables of related party transactions over multiple years and explanations of the company's internal checks and governance regarding these matters. It references an administrative penalty notice and ongoing regulatory investigation but does not contain full financial statements or comprehensive financial performance data. The document is a regulatory announcement addressing compliance and legal matters related to related party transactions and control issues, rather than a full annual or interim report, earnings release, or audit report. It is not a certification letter, nor a simple notice of report publication. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement and compliance disclosure that does not fit other specific categories.
2019-10-09 Chinese
监事辞职公告
Board/Management Information Classification · 100% confidence The document is a resignation announcement of a company supervisor (监事辞职公告) from 江苏四环生物股份有限公司. It details the resignation of a board-level supervisor due to personal health reasons and the impact on the board's composition. There is no financial data, no report or presentation, no voting results, no legal proceedings, no capital changes, and no earnings information. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2019-09-23 Chinese
关于收到行政处罚及市场禁入事先告知书的公告
Regulatory Filings Classification · 100% confidence The document is a detailed announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding administrative penalties and market ban notices issued by the China Securities Regulatory Commission (CSRC). It describes investigations, violations of securities laws, penalties, and sanctions against the company and individuals related to false disclosures, failure to report shareholdings, and illegal trading activities. The document is not a financial report, earnings release, or management discussion but a regulatory announcement about legal and compliance issues and penalties. It is a formal regulatory filing informing the market and investors about enforcement actions and sanctions. Therefore, the document fits best under the category of Regulatory Filings (RNS).
2019-09-22 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding changes in accounting policies, specifically the adoption of new financial instrument standards and revised financial statement formats effective from 2019. It details the reasons for the change, the new accounting policies adopted, the impact on financial statements, and includes opinions from the board, independent directors, and the supervisory board. The document is relatively short (3537 characters) and serves as a formal disclosure of accounting policy changes rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2019-08-30 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.